The EPIC-Norfolk Eye Study: rationale, methods and a cross-sectional analysis of visual impairment in a population-based cohort. by Khawaja, AP et al.
The EPIC-Norfolk Eye Study:
rationale, methods and a cross-sectional
analysis of visual impairment in a
population-based cohort
Anthony P Khawaja,1 Michelle P Y Chan,2 Shabina Hayat,1 David C Broadway,3
Robert Luben,1 David F Garway-Heath,4 Justin C Sherwin,1 Jennifer L Y Yip,1
Nichola Dalzell,1 Nicholas J Wareham,5 Kay-Tee Khaw,1 Paul J Foster2,4
To cite: Khawaja AP,
Chan MPY, Hayat S, et al.
The EPIC-Norfolk Eye Study:
rationale, methods and a
cross-sectional analysis of
visual impairment in a
population-based cohort.
BMJ Open 2013;3:e002684.
doi:10.1136/bmjopen-2013-
002684
▸ Prepublication history for
this paper are available
online. To view these files
please visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-002684).
Received 4 February 2013
Revised 15 February 2013
Accepted 22 February 2013
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered affiliations see
end of article.
Correspondence to
Professor Paul J Foster;
p.foster@ucl.ac.uk
ABSTRACT
Objectives: To summarise the methods of the
European Prospective Investigation of Cancer (EPIC)-
Norfolk Eye Study, and to present data on the
prevalence of visual impairment and associations with
visual impairment in the participants.
Design: A population-based cross-sectional study
nested within an on-going prospective cohort study
(EPIC).
Setting: East England population (the city of Norwich
and its surrounding small towns and rural areas).
Participants: A total of 8623 participants aged
48–92 years attended the Eye Study and underwent
assessment of visual acuity, autorefraction, biometry,
tonometry, corneal biomechanical measures, scanning
laser polarimetry, confocal scanning laser
ophthalmoscopy, fundal photography and automated
perimetry.
Outcome measures: Visual impairment was defined
according to the WHO classification and the UK driving
standard, and was based on presenting visual acuity.
Summary measures of other ophthalmic measurements
are also presented.
Results: The prevalence (95% CI) of WHO-defined
moderate-to-severe visual impairment and blindness was
0.74% (0.55% to 0.92%). The prevalence (95% CI) of
presenting visual acuity worse than the UK driving
standard was 5.87% (5.38% to 6.37%). Older age was
significantly associated with visual impairment or
blindness (p<0.001). Presenting visual acuity worse than
UK driving standard was associated with older age
(p<0.001), female sex (p=0.005) and lower educational
level (p=0.022).
Conclusions: The prevalence of blindness and visual
impairment in this selected population was low. Visual
impairment was more likely in older participants, women
and those with a lower educational level.
INTRODUCTION
The European Prospective Investigation of Cancer
(EPIC) is a 10-country collaborative study
which started in 1989.1 2 EPIC-Norfolk, one of
the UK centres, recruited 30 445 men and
women resident in East Anglia, aged 40–
79 years, between 1993 and 1997.3 The initial
aim of EPIC was to examine the dietary deter-
minants of cancer. However, the aims of
EPIC-Norfolk were broadened to identify
other determinants of chronic disease. Visual
health assessment was included in the latest
health examination (HE), and this is referred
to as the EPIC-Norfolk Eye Study.
ARTICLE SUMMARY
Article focus
▪ The European Prospective Investigation of
Cancer-Norfolk Eye Study is part of an on-going
UK population-based cohort study.
▪ This article describes the methods of the Eye
Study component and the characteristics of the
participants.
▪ In particular, the article presents the prevalence
of visual impairment in the cohort, and sociode-
mographic associations with visual impairment.
Key messages
▪ In total, 8623 participants aged 48–92 years
attended the Eye Study.
▪ While the prevalence of visual impairment or
blindness was low due to the selected nature of
the population, more than 5% of participants did
not reach UK driving standard equivalent acuity.
▪ Visual impairment was more likely in participants
who were older, women and with lower educa-
tional achievement.
Strengths and limitations of this study
▪ Large study sample.
▪ Selected population susceptible to significant
healthy volunteer bias.
▪ Associations examined are cross-sectional and
therefore limit causal inference.
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According to Sight Loss UK, in 2010 there were 1.86
million people in the UK with sight loss sufﬁcient to
have a signiﬁcant impact on their daily lives; an increase
from 1.8 million in 2008.4 5 Age-related macular degen-
eration (AMD) was the leading cause of certiﬁed visual
loss, followed by glaucoma.6 Glaucoma remains the
leading cause of irreversible blindness globally.7 The
overall aim of the EPIC-Norfolk Eye Study is to further
understand, in a selected, predominantly White British
population, of the determinants of visual health, with an
emphasis on glaucoma. The speciﬁc objectives of the
EPIC-Norfolk Eye Study are to:
1. Describe the distribution of structural aspects of the
eye within the cohort, including axial length, anterior
chamber depth, corneal curvature, refractive error,
optic nerve tomography and retinal nerve ﬁbre layer
(RNFL) tomography.
2. Describe the distribution of functional measures
within the cohort, including visual acuity (VA) and
visual ﬁeld parameters.
3. Describe the frequency of ocular disease within the
cohort, including uncorrected refractive error, glau-
coma, AMD, diabetic retinopathy and other retinal
diseases.
4. Determine associations of the above parameters and
diseases with demographic factors and exposure mea-
sures available for the EPIC-Norfolk cohort, includ-
ing nutritional and lifestyle measures, biological
markers and genetic risk factors.
5. Assess the diagnostic performance of different measures
using new ophthalmic assessment tools for glaucoma.
The objectives of this article were to (1) describe the
methods for the EPIC-Norfolk Eye Study and the base-
line characteristics of participants in the Eye Study, (2)
describe the frequency and causes of visual impairment
in the cohort and (3) describe the sociodemographic
associations with visual impairment in the cohort.
METHODS/DESIGN
Ethics
The EPIC-Norfolk Eye Study was carried out following
the principles of the Declaration of Helsinki and the
Research Governance Framework for Health and Social
Care. The study was approved by the Norwich Local
Research Ethics Committee (05/Q0101/191) and East
Norfolk & Waveney National Health Service (NHS)
Research Governance Committee (2005EC07L). All par-
ticipants gave written, informed consent.
Study location
The study location is in the East of England and com-
prises the city of Norwich and its surrounding small
towns and rural areas (ﬁgure 1). This region has the
advantage of being served by one major university teach-
ing hospital and by having little outward migration for
the study age group.3 Study population stability facili-
tates outcome ascertainment through linkage to
hospital-based disease records, and helps to limit loss to
follow-up in the long term. The cohort is 99.7% White
and has fewer smokers than the general UK population.3
Otherwise, the cohort is comparable with the UK
general population in terms of anthropometric variables,
blood pressure and serum lipids.3
Recruitment
Participant recruitment to EPIC-Norfolk is summarised
in ﬁgure 2. Baseline recruitment was by invitation of resi-
dents aged 40–79, via 35 participating general practices,
between 1993 and 1997. Since virtually all residents in
the UK are registered with a general practitioner
through the NHS, general practice lists serve as popula-
tion registers. Detailed EPIC methods have been pub-
lished elsewhere.3 All living participants who had not
opted out of the study were invited to take part in the
third HE (n=18 380), of which 11 110 (60%) agreed to
take part. Of these, 8623 (47%) completed the examin-
ation prior to closure of the study at the end of the
grant funding.
Examination procedures
There are extensive data available from the examina-
tions undertaken at two previous rounds, and interven-
ing postal questionnaires; these have included
questionnaires regarding lifestyle (5 timepoints), phys-
ical activity (2 timepoints) and psychosocial domains (2
timepoints). Nutritional assessment comprised food fre-
quency questionnaires (3 timepoints), 7-day food diaries
(4 timepoints) and blood and urine biomarkers (3 time-
points). DNA is available for the whole EPIC-Norfolk
cohort with varying degrees of genotyping having been
conducted to date.
The focuses for data collection in the 3HE were visual
health (EPIC-Norfolk Eye Study), cognition (8 validated
tests assessing different domains of cognitive function),
skin ageing (digital photographs under standardised
conditions), physical activity (accelerometer and ques-
tionnaire), physical performance and muscle strength
(modiﬁed version of the Established Populations for
the Epidemiologic Studies of the Elderly battery).8
Furthermore, anthropometry (height, weight, waist cir-
cumference, hip circumference), blood pressure, heel-
bone ultrasound, impedance/body fat percentage, ankle
brachial pressure, lung function and blood sampling
were performed. The 3HE lasted between 150 and
180 min, with the Eye Study component lasting approxi-
mately 40 min.
All ocular measurements were undertaken by trained
nurses following Moorﬁelds Eye Hospital standard oper-
ating procedures adapted for the EPIC-Norfolk Eye
Study. Intensive periods of staff training and validation
were undertaken before the project started. Refresher
training was provided at least annually and data were
reviewed weekly by an ophthalmologist. All Eye Study
examinations were undertaken without pupil dilation,
and were as follows:
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▸ Ophthalmic history: A detailed ophthalmic history was
elicited from participants, including details of previ-
ous ocular diagnoses and management, subjective VA,
and family history of eye disease.
▸ VA: Monocular VA was measured using a LogMAR
(Logarithm of the Minimum Angle of Resolution)
chart (Precision Vision, LaSalle, Illinois, USA) on a
light box under standard illumination. Chart ‘1’ was
used for all measurements. The test was carried out
with the aid of the participant’s usual distance correc-
tion at 4 m (or 2 m then 1 m if unable to read any
letters). The test was terminated when the participant
was able to read ≤3 letters on a line and testing
repeated using pinhole-correction if participants were
unable to read 3 letters on the 0.3 line. Standard
letter-by-letter scoring was used to derive LogMAR
VA. If a participant failed to read any letters at 1 m,
further testing comprised counting ﬁngers at 30 cm,
followed by hand movements at 30 cm, followed by
perception of light using a handheld torch.
▸ Refractive error: Refractive error was measured using a
Humphrey Auto-Refractor 500 (Humphrey Instruments,
San Leandro, California, USA).
▸ Ocular dimensions: Biometry was conducted using non-
contact partial coherence interferometry (IOLMaster
V.4, Carl Zeiss Meditech Ltd, Welwyn Garden City,
UK). For each eye, ﬁve measurements of axial length,
three measurements of corneal curvature and one
measurement of anterior chamber depth were taken.
Axial length measurements were repeated if ﬂagged
as more than 0.1 mm different to the others.
▸ Tonometry and corneal biomechanical measures: Intraocular
pressure (IOP) was measured on the ﬁrst 443 partici-
pants using an AT555 Non-Contact Tonometer
(Reichert, New York, USA). Three readings were taken
for each eye, and measures were repeated if ﬂagged as
suspect (more than 5 mmHg different to the other
two). For all subsequent participants, IOP was mea-
sured using the Ocular Response Analyzer (ORA,
Reichert, New York, USA; software V.3.01) which also
measures corneal biomechanical attributes.9 Three
readings were taken per eye following a demo puff.
ORA measurements with a poor quality pressure wave-
form were repeated.
▸ RNFL imaging: Scanning laser polarimetry (GDx VCC,
Zeiss, Dublin, California, USA) was used to assess
the peripapillary RNFL. Spherical equivalent values
derived from the autorefractor were inputted. Initially
a corneal scan was taken, followed by the RNFL scan.
If the macular ellipse for corneal compensation was
Figure 1 A map of Norfolk. Boxes with crosses in represent general practices that European Prospective Investigation of
Cancer -Norfolk Eye Study participants attend; the larger the box, the larger the number of participants. Boxes without a cross
represent general practices which no participants currently attend.
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not well centred, it was modiﬁed accordingly. If an
RNFL scan was not of sufﬁcient quality (less than 7
quality score), it was repeated once.
▸ Optic nerve head topography: Scanning laser ophthal-
moscopy (Heidelberg Retinal Tomograph (HRT) II,
Heidelberg Engineering, Heidelberg, Germany) was
used to assess optic nerve head anatomy. The partici-
pant’s keratometry was entered prior to scanning. If
the image quality was poor (topography SD >40 μm)
a repeat scan was undertaken. Contours around the
disc margins were manually drawn and subsequently
checked by an ophthalmologist (and redrawn if
necessary). The HRT software was subsequently
updated to Glaucoma Module Premium Edition (soft-
ware V.3.1) and data exported following this. These
data are equivalent to HRT3-derived parameters.
▸ Fundus photography: Digital photographs of the optic
disc and macula were taken using a TRC-NW6S non-
mydriatic retinal camera and IMAGEnet Telemedicine
System (Topcon Corporation, Tokyo, Japan) with a 10
megapixel Nikon D80 camera (Nikon Corporation,
Tokyo, Japan). The photographs are undergoing
masked grading for AMD, diabetic retinopathy, other
retinopathy and optic disc parameters.
▸ Automated perimetry: Visual ﬁelds were assessed in all
participants meeting predetermined criteria and 1 in
10 participants not meeting the criteria, if time per-
mitted (box 1). A Central 24–2 threshold algorithm
on a Humphrey 750i Visual Field Analyzer (Carl Zeiss
Meditech Ltd, Welwyn Garden City, UK) was used.
Autorefractor results were inputted, and the trial lens
calculated.
Referral criteria
All test results were reviewed by an ophthalmologist and
participants meeting predeﬁned criteria (box 1) were
referred to a glaucoma specialist (DCB) at the major local
ophthalmic department (Norfolk & Norwich University
Hospitals (NNUH) NHS Foundation Trust). Participants
referred underwent a full ophthalmic examination, by a
glaucoma fellowship-trained ophthalmologist, including
tonometry, pachymetry, gonioscopy, optic disc imaging and
automated perimetry if clinically indicated. For participants
already known to the NNUH who did not require add-
itional review, a summary of their case notes and any study-
related data were sent to the EPIC-Norfolk Eye Study
coordinator. In total, 1703 participants were referred.
Power and statistical methods
For continuous outcome measures, the study is powered to
detect a difference of 10% of SD, with 90% power at a 5%
Box 1 Criteria applied to determine whether a participant
should undergo automated perimetry, or be referred for
hospital examination
Criteria for automated perimetry
Any one of:
▪ IOP >24 mm Hg
▪ Any HRT II Moorfields Regression Analysis sector outside
normal limits.
▪ Abnormal GDx RNFL average thickness/ standard deviation/
superior thickness/inferior thickness measures (1 reading at
p<0.5% or 2 readings p<1% or 3 readings p<2%).
▪ IOP >21 mm Hg AND either an abnormal HRT II Moorfields
Regression Analysis (at least two sectors borderline) or
abnormal GDx RNFL average thickness/standard deviation/
superior thickness/inferior thickness measures (any two
readings p<5%).
▪ In addition to this, perimetry was conducted in 1 in 10 parti-
cipants not meeting the criteria, if time permitted.
Criteria for referral to hospital clinic
Any one of:
▪ Best-corrected VA >0.34 LogMAR in either eye.
▪ IOP >24 mm Hg in either of the eyes.
▪ IOP >21 mm Hg in either of the eyes with ≥3 borderline
HRT II sectors on Moorfields Regression Analysis.
▪ GDx RNFL average thickness/standard deviation/superior
thickness/inferior thickness measures outside normal limits
in either of the eyes (1 reading at p<0.5% or 2 readings
p<1% or 3 readings p<5%).
▪ Any HRT II sector Moorfields Regression Analysis outside
normal limits.
▪ Manifest abnormalities on fundus photography in either of
the eyes.
▪ HRT, Heidelberg retinal tomograph; IOP, intraocular pres-
sure; RNFL, retinal nerve fibre layer; VA, visual acuity.
Figure 2 A flow chart detailing participant recruitment for the
European Prospective Investigation of Cancer -Norfolk Eye
Study.
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signiﬁcance level (eg, 0.36 mmHg for IOP, or 0.02 for
HRT linear cup-to-disc ratio). For case–control analyses of
primary open-angle glaucoma, using an estimated projec-
tion of 132 ‘deﬁnite’ cases, the study provides 90% power
at a 5% signiﬁcance level to detect an OR of 1.83, assum-
ing an exposure prevalence of 25% in the controls.
For the analyses in this manuscript, comparisons of base-
line characteristics were carried out using independent
sample t tests for continuous variables (age and body mass
index (BMI), both normally distributed) and the χ2 test
for categorical variables. Presenting VA (PVA) was deﬁned
as the VA in the better eye, wearing usual correction if
used. Rates of visual impairment were directly standardised
to the mid-2010 population of England by age and sex.
Causes of visual impairment were ascertained from hos-
pital referral data or from self-report if the participant was
not referred (nurse ascertained ophthalmic history at
the HE or questionnaire ascertained). To test for associa-
tions with visual impairment and blindness, multiple logis-
tic regression models were constructed containing age,
sex, BMI, social class, education level and smoking
status. Social class was recorded according to the
Registrar-General’s occupation-based classiﬁcation system;
this was based on the participant’s last occupation if they
were retired. Educational level was recorded and classiﬁed
into four groups according to the highest qualiﬁcation
achieved. Smoking status was dichotomised (never/ever)
since there were small numbers who were current
smokers. For the purposes of the summary data, best-
corrected VA was described (deﬁned as the better of PVA
or pinhole-corrected VA in the better eye). Stata V.12.1
(StataCorp LP, Texas, USA) was used for all analyses.
Publications to date
Interim data on a proportion of the cohort have been pub-
lished, prior to the closure of the EPIC-Norfolk Eye Study.
Publications include articles related to IOP and corneal
biomechanical measures,10 refractive error,11 uncorrected
refractive error,12 and an association between physical
activity and ocular perfusion pressure.13
RESULTS
In total, 8623 participants aged 48–92 years were seen at
the 3HE, representing 28% of the original 30 445 parti-
cipants who consented for the study at baseline between
1993 and 1997. Of those attending 3HE, 8011 (94%)
had also attended the 1HE. The remaining 513 partici-
pants consented at baseline, but did not attend the
1HE. Table 1 compares the baseline characteristics of
those who attended both 1HE and 3HE with those who
attended 1HE only. Participants attending the 3HE were
signiﬁcantly younger, of lower BMI, higher social class,
higher educational achievement level and less were
smokers than those attending the 1HE only (all
p<0.001). Table 2 summarises the numbers of partici-
pants completing each test and summary measures for
these tests.
Table 1 Comparison of baseline characteristics between participants attending the first health examination only (1HE) and
participants attending both the European Prospective Investigation of Cancer -Norfolk Eye Study (ENES) and 1HE
Attended 1HE only Attended ENES & 1HE
(n= 17529) (n=8110) p Value
Age at 1HE (n=25639) 60.8 (9.5) 55.8 (7.9) <0.001
Sex (n=25639) 0.13
Male 7992 (46%) 3615 (45%)
Female 9537 (54%) 4495 (55%)
BMI at 1HE (n=25585) 26.6 (4.0) 25.8 (3.7) <0.001
Social class (n=25069) <0.001
Professional 1041 (6%) 713 (9%)
Managerial/technical 5835 (34%) 3323 (41%)
Skilled non-manual 2841 (17%) 1298 (16%)
Skilled manual 4135 (24%) 1637 (20%)
Partly skilled 2478 (15%) 883 (11%)
Unskilled 702 (4%) 183 (2%)
Education level (n=25621) <0.001
Degree 1858 (11%) 1431 (18%)
A level 6666 (38%) 3590 (44%)
O Level 1657 (9%) 965 (12%)
Less than O level 7332 (42%) 2122 (26%)
Smoking status (n=25419) <0.001
Current 2279 (13%) 705 (9%)
Former 7615 (44%) 3146 (39%)
Never 7447 (43%) 4227 (52%)
Note that the 513 participants who only attended the ENES are not in this table. There were missing data for body mass index (BMI), social
class, education level and smoking status, reflected in the total numbers presented. Mean (SD) is presented for continuous variables and
number (percentage) for categorical variables.
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The proportions of participants with different categor-
ies of VA impairment according to WHO deﬁnitions14
and the driving standard in the UK15, are presented in
table 3. The causes of impairment in those classiﬁed as
blind or visually impaired by WHO criteria are sum-
marised in table 4. Where there was more than one sig-
niﬁcant contributory cause to the visual impairment, all
conditions were speciﬁed.
Sociodemographic characteristics of the participants
stratiﬁed by visual impairment categories are presented in
table 5. Results from the logistic regression models exam-
ining associations with visual impairment are summarised
in table 6. These are based on participants with complete
data on all covariates (n=8411). An increased odds of
visual impairment or blindness was associated with older
age (p<0.001) and there was a trend towards increasing
odds with lower social class (p=0.09) and lower
educational achievement level (p=0.08). An increased
odds of PVA worse than UK driving standard was asso-
ciated with older age (p<0.001), female sex (p=0.005),
and there were trends for association with lower social
class (p=0.09) and lower educational achievement level
(p=0.022).
DISCUSSION
The EPIC-Norfolk Eye Study is part of a prospective
cohort study with a wealth of exposure measures
obtained over a period of nearly two decades. The
overall aim of the Eye Study was to further understand-
ing of common eye diseases by examination of the epi-
demiology and associations within the cohort. Strengths
of the EPIC-Norfolk Eye Study include the large sample
size, the detailed ophthalmic phenotyping (particularly
Table 3 Distribution of presenting visual acuity in the better eye of participants (n=8563), according to different
classifications of vision loss
LogMAR
(better eye)
Snellen
equivalent Classification n
Crude prevalence
(95% CI)
Adjusted
prevalence (%)
>1.30 <3/60 WHO Blindness 6 0.07% (0.01 to 0.13) 0.05
>1.00 ≤1.30 <6/60 ≥3/60 WHO Severe Visual Impairment 8 0.09% (0.03 to 0.16) 0.05
>0.48 ≤1.00 <6/18 ≥6/60 WHO Moderate Visual Impairment 49 0.57% (0.41 to 0.73) 0.44
>0.48 <6/18 Visual impairment (including blindness) 63 0.74% (0.55 to 0.92) 0.55
>0.22 <6/10 Below UK driving standard equivalent 503 5.87% (5.38 to 6.37) 5.65
Adjusted figures represent rates directly standardised to the mid-2010 population of England by age and sex.
Table 2 Summary of numbers of participants completing each test in the European Prospective Investigation of
Cancer-Norfolk Eye Study, and summary statistics from these tests
Test
Number (%)
completing test Summary measure
Visual acuity 8563 (99%) Median LogMAR BCVA (IQR) in better eye –0.02 (–0.08, 0.04)
Median LogMAR BCVA (IQR) in worse eye 0.06 (0.00, 0.16)
Refraction 8513 (99%) Mean spherical equivalent (SD), dioptres 0.17 (2.25)
Number (%) moderate myopes (≤–3 >–6 D) 695 (8.2%)
Number (%) high myopes (≤–6 D) 234 (2.7%)
Ocular dimensions 8033 (93%) Mean axial length (SD) (mm) 23.55 (1.19)
Mean anterior chamber depth (SD) (mm) 3.16 (0.46)
Tonometry 8401 (97%) Mean IOP (SD) (mm Hg) 16.3 (3.6)
Number (%) ocular hypertension (IOP>21) 1,161 (13.8%)
Corneal biomechanics 7958 (92%) Mean corneal hysteresis (SD) (mm Hg) 10.1 (1.6)
Mean corneal resistance factor (SD) (mm Hg) 10.3 (1.7)
Scanning laser polarimetry 7943 (92%) Mean RNFL thickness (SD) (μm) 57.8 (8.9)
Mean Nerve Fibre Indicator (SD) 19.3 (10.1)
Scanning laser ophthalmoscopy 8064 (94%) Mean disc area (SD) (mm2) 1.88 (0.42)
Mean rim area (SD) (mm2) 1.41 (0.34)
Mean linear cup-to-disc ratio (SD) 0.54 (0.17)
Fundus photography 7519 (87%) Grading in process –
Automated perimetry 966 (11%) Median mean deviation (IQR), decibels –1.38 (–3.24, –0.14)
759 met criteria
207 control
The total number attending the third health examination was 8623. Note that this represents the tests carried out at the research clinic visit,
and does not include any tests carried out at the referral visit in the hospital clinic. Values represent the mean of right and left measures,
except for visual acuity (better and worse eye measures are presented).
BCVA, best-corrected visual acuity; D, dioptres; IOP, Goldmann correlated intraocular pressure; RNFL, retinal nerve fibre layer.
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with respect to optic nerve anatomy) and the large
number of participants referred for a clinical examin-
ation at the local hospital and the detailed data available
from these visits. There are several limitations of the
design of the study. The eye study population is highly
selected and healthier than the baseline cohort (signiﬁ-
cantly younger, of lower BMI, higher social class, higher
educational achievement level and fewer were smokers
(all p<0.001)). These differences may limit generalisa-
tion and introduce bias if disease associations are differ-
ent in healthier volunteers. The EPIC-Norfolk Eye Study
is cross-sectional at present and while many exposure
measures were obtained prior to the ophthalmic mea-
surements, it is not possible to exclude undiagnosed
ophthalmic disease being present at earlier HEs. This
may limit causal inference for any associations exam-
ined. Another limitation is that automated perimetry was
not carried out for all participants and slit lamp examin-
ation and gonioscopy were only performed in those
meeting set referral criteria. Functional loss may some-
times precede measureable structural damage in glau-
coma and failure to assess visual ﬁeld can miss up to a
third of primary open-angle glaucoma cases.16 Fundus
photography was non-mydriatic, and this may limit the
Table 5 Sociodemographic characteristics of participants stratified by WHO visual impairment category
Blindness
Severe visual
impairment
Moderate visual
impairment
Visual
impairment
(including
blindness) Rest of cohort
p Value
LogMAR (better eye) >1.30 >1.00 ≤1.30 >0.48 ≤1.00 >0.48 ≤0.48
Snellen equivalent <3/60 <6/60 ≥3/60 <6/18 ≥6/60 <6/18 ≥6/18
(n=6) (n=8) (n=49) (n=63) (n=8500)
Age (n=8563) 79.6 (10.7) 80.2 (5.6) 74.6 (8.1) 75.8 (8.3) 68.6 (8.1) <0.001
Sex (n=8563) 0.84
Male 4 (67%) 5 (63%) 20 (41%) 29 (46%) 3807 (45%)
Female 2 (33%) 3 (38%) 29 (59%) 34 (54%) 4693 (55%)
BMI (n=8558) 26.0 (3.0) 28.9 (2.8) 26.0 (4.5) 26.3 (4.3) 26.8 (4.3) 0.36
Social class (n=8484) 0.06
Professional 0 (0%) 0 (0%) 5 (10%) 5 (8%) 739 (9%)
Managerial/technical 2 (33%) 3 (38%) 11 (23%) 16 (26%) 3470 (41%)
Skilled non-manual 1 (17%) 2 (25%) 8 (17%) 11 (18%) 1358 (16%)
Skilled manual 1 (17%) 1 (13%) 15 (31%) 17 (27%) 1730 (21%)
Partly skilled 2 (33%) 2 (25%) 5 (10%) 9 (15%) 934 (11%)
Unskilled 0 (0%) 0 (0%) 4 (8%) 4 (6%) 191 (2%)
Education level (n=8561) <0.001
Degree 1 (17%) 1 (13%) 7 (14%) 9 (14%) 1498 (18%)
A level 3 (50%) 2 (25%) 14 (29%) 19 (30%) 3758 (44%)
O level 0 (0%) 0 (0%) 2 (4%) 2 (3%) 1021 (12%)
Less than O level 2 (33%) 5 (63%) 26 (53%) 33 (52%) 2221 (26%)
Smoking status (n=8442) 0.47
Current 0 (0%) 0 (0%) 3 (6%) 3 (5%) 368 (4%)
Former 3 (60%) 3 (38%) 22 (47%) 28 (47%) 3297 (39%)
Never 2 (40%) 5 (63%) 22 (47%) 29 (48%) 4717 (56%)
There were 8563 participants with visual acuity data, and varying numbers with missing data for other variables as indicated by n next to each
variable. Age, body mass index (BMI) and smoking status were ascertained at the Eye Study (third health examination). Social class and
education were ascertained at the first health examination. p Value is for comparison between ‘Visual impairment (including blindness)’ and
‘Rest of cohort’.
Table 4 Causes of visual impairment in those classified
as blind or visually impaired by WHO criteria (n=63)
Cause of visual impairment n
Per
cent
Uncorrected refractive error 17 28
Age-related macular degeneration 13 22
Cataract 6 10
Glaucoma 4 7
Amblyopia+cataract 3 5
Cataract+retinal vein occlusion 2 3
Congenital (unspecified) 2 3
Myopic macular degeneration 2 3
Retinal detachment 2 3
Amblyopia+epiretinal membrane 1 2
Amblyopia+macular hole 1 2
Amblyopia+retinal vein occlusion 1 2
Corneal pathology requiring grafts
(unknown)
1 2
Optic neuritis 1 2
Retinitis pigmentosa 1 2
Visual cortex atrophy 1 2
Unknown 5 8
Total 63 100
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number of images of suitable quality for detailed
grading. However, it is anticipated that most images will
be of sufﬁcient quality to detect moderate disease, such
as signiﬁcant AMD, and to assess optic disc parameters.
Rates of visual impairment in the EPIC-Norfolk Eye
Study cohort were very low. According to WHO
criteria,14 0.07% (95% CI 0.01% to 0.13%) of the parti-
cipants were blind, and 0.74% (0.55% to 0.92%) were
blind or had moderate-to-severe visual impairment.
The EPIC-Norfolk Eye Study rates are lower than those
reported by other UK studies, and this is likely to be due
to selection bias causing an underestimate. Given the
required self-completion of questionnaires and travelling
to the study clinic, it was less likely that individuals with
signiﬁcant visual impairment would take part. Rates
of visual impairment in two UK populations aged over
65 years were reported to be 14.3% (criterion <6/18)17
and 30% (criterion <6/12),18 and was reported to be
12.5% (criterion <6/18) in a UK population over
75 years of age.19 Prevalence of visual impairment (<6/
18) was reported to be 0.90% in participants of the 1958
British birth cohort study aged 44 or 45 years.20 In add-
ition to WHO criteria for visual impairment, we also pre-
sented data on PVA worse than the UK driving standard,
as this represents an important sociofunctional thresh-
old and, to the best of our knowledge, has not been
reported previously at a population level. We found
that over 5% of participants did not meet the equivalent
acuity standard for driving in the UK. While this is not
a high proportion, it may be signiﬁcant given the
importance of driving for maintaining independence,
especially in rural areas. We also presented visual impair-
ment prevalence rates adjusted to the age and sex distri-
bution of the mid-2010 population of England. However,
given the healthy nature of the cohort, these should not
be interpreted as representative rates for the English
population.
Of the 63 participants with visual impairment or blind-
ness, 28% were secondary to uncorrected refractive
error. This high rate of potentially reversible visual
impairment (with glasses or a new glass prescription) is
consistent with the 26% of participants aged 75 years or
older reported in the MRC Trial of the Assessment and
Management of Older People in the Community.21 The
next most common causes of visual impairment were
AMD followed by cataract and glaucoma. This is consist-
ent with the other UK population-based studies that
have published causes of visual impairment.18 21
Despite the limited generalisability of the cohort visual
impairment prevalence, the data provides potential to
examine associations with visual impairment. Age was an
important determinant with a twofold to threefold increase
in odds of visual impairment or PVA worse than UK driving
standard (<6/10) per decade of increasing age. Women
Table 6 Multivariable logistic regression results
Visual impairment (including blindness) Below UK driving standard
(<6/18) n=60 (<6/10) n=484
OR 95% CI p Value OR 95% CI p Value
Age (per 10 years) 2.76 (1.97 to 3.86) <0.001 2.48 (2.20 to 2.81) <0.001
Sex
Male Ref Ref
Female 1.09 (0.63 to 1.87) 0.76 1.33 (1.09 to 1.63) 0.005
BMI (per 5 Kg/m2) 0.90 (0.65 to 1.24) 0.53 0.95 (0.85 to 1.06) 0.37
Social class
Professional Ref Ref
Managerial/technical 0.68 (0.24 to 1.93) 0.47 0.98 (0.67 to 1.45) 0.93
Skilled non-manual 1.06 (0.33 to 3.34) 0.93 1.29 (0.84 to 1.96) 0.25
Skilled manual 1.29 (0.42 to 3.94) 0.65 1.28 (0.84 to 1.96) 0.25
Partly skilled 1.08 (0.32 to 3.70) 0.90 1.12 (0.70 to 1.79) 0.64
Unskilled 2.47 (0.59 to 10.37) 0.22 1.29 (0.65 to 2.53) 0.47
Test for trend 1.03 (1.00 to 1.06) 0.09 1.01 (1.00 to 1.02) 0.09
Education level
Degree Ref Ref
A level 0.63 (0.27 to 1.49) 0.29 1.25 (0.90 to 1.72) 0.18
O level 0.15 (0.02 to 1.24) 0.08 1.34 (0.89 to 2.02) 0.16
Less than O level 1.34 (0.56 to 3.21) 0.51 1.49 (1.05 to 2.11) 0.024
Test for trend 1.26 (0.97 to 1.64) 0.08 1.12 (1.02 to 1.23) 0.022
Smoking status
Never Ref Ref
Ever 1.39 (0.80 to 2.39) 0.24 1.19 (0.98 to 1.45) 0.08
OR and 95% CI for the WHO definition of visual impairment/blindness, and better eye presenting visual acuity worse than the UK driving
standard. All variables presented were included together in each of the two models. Results are for participants with complete data for all the
variables presented (n=8411).
BMI, body mass index.
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were more likely to have VA worse than 6/10, independ-
ently of age, which is in keeping with other UK studies.17 19
A previously published meta-analysis has demonstrated an
OR of 1.63 (95% CI 1.30 to 2.05) for blindness in women
compared with men in industrialised countries, using an
age-stratiﬁed approach.22 However, due to smaller
numbers, all age groups over 70 years were pooled for the
meta-analysis. Therefore, this difference could have been
due to higher rates of AMD in women who live longer in
this age group (residual confounding by age within the
over 70 years stratum). Another possible explanation for
the higher observed rates in women is differential access to
ophthalmic healthcare. However, in the EPIC-Norfolk Eye
Study, women were more likely to have had cataract surgery
than men (12.8% vs 9.9%. p<0.001), this indicates higher
access to ophthalmic care. There were also trends for visual
impairment in participants of lower social class and lower
educational achievement level. A recently published review
highlighted the evidence for the link between visual
impairment and social class or education.23 Furthermore,
it was reported recently that participants in the Los
Angeles Latino Eye Study with incident visual impairment
had spent less time in education, and were more likely to
be unemployed.24
In summary, the EPIC-Norfolk Eye Study is a large
ophthalmic epidemiological study nested within an
on-going cohort study of a predominantly White British
population. While the prevalence of visual impairment
or blindness was low due to the selected nature of
the population, more than 5% of participants did not
reach UK driving standard equivalent acuity. The study
provides evidence for higher rates of visual impairment
in those who are older, women and with lower educa-
tional achievement.
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